A recent study found VATS resection in CT-screened high-risk Danish population yielded higher incidence of early stage lung cancer. The study detected 68 lung cancers in the screened group versus 24 in the unscreened group, with 51 patients suitable for surgery and 84% undergoing VATS.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
Researchers found that tenasin-C gene expression and nodule size can predict lung cancer with improved accuracy. The study used bronchoscopic microsampling to collect fluid from lung nodules, showing promise for a less invasive diagnostic technique.
Researchers found that fine needle aspiration is highly sensitive for diagnosing lung cancer, but has a high rate of false negatives, especially in larger lesions. The study recommends repeat imaging to monitor for growth and suggests this method can help patients avoid unnecessary surgery.
A recent study published in the Journal of Thoracic Oncology reveals that Japanese patients with lung cancer are more likely to harbor specific genetic mutations and have a different risk profile compared to Western patients. The research highlights the importance of considering genetic factors in lung cancer diagnosis and treatment.
Researchers analyzed four studies and found that regular follow-up reduces crisis-driven health episodes. While no preferred method was determined, the authors recommend guidelines for initial specialist appointments and protocol-driven follow-up led by a lung cancer clinical nurse specialist.
A recent study published in Journal of Thoracic Oncology suggests that CYFRA21-1 levels can reliably indicate patient response to chemotherapy for non-small cell lung cancer (NSCLC). Higher baseline concentrations were linked to poorer overall and failure-free survival. Further research is needed to confirm these findings.
A recent study published in the Journal of Thoracic Oncology suggests that pleurectomy/decortication (P/D) is a superior approach to extrapleural pnemonectomy (EPP) for patients with early-stage malignant pleural mesothelioma. P/D resulted in significantly better survival rates and lower mortality and morbidity compared to EPP.
A panel of 10 serum protein biomarkers shows promise in predicting lung cancer risk and aiding early detection. Research suggests that these biomarkers could reduce the number of unnecessary lung biopsies needed, offering a more targeted approach to diagnosis.
Lung cancer patients face geographic challenges to access clinical trials due to molecular preselection. Researchers propose using online patient communities and innovative trial approaches to inform patients about trials, accelerate research, and address practical challenges in conducting personalized medicine trials.
Research finds a significant association between pulmonary TB and EGFR mutations in lung cancer patients. The study reveals that tumors with these mutations respond well to targeted therapies, offering new hope for treatment.
The IASLC has set up a Strategic CT Screening Advisory Committee to define optimal approaches to lung cancer screening. The committee will focus on six key components, including identifying high-risk individuals and developing radiological guidelines for national screening programs.
Researchers found that lung cancer patients with diabetes had higher survival rates, including 43% at 1-year and 28% without diabetes. The benefits were seen across different stages of disease, suggesting that diabetes may not be a reason to withhold standard treatment.
A study found that ALK-rearranged non-small cell lung cancer patients responded significantly better to pemetrexed than those without the genetic mutation. Researchers discovered that ALK positivity was an independent predictor for pemetrexed efficacy, with improved tumor response rates and longer time to progression.
Researchers found that fibrous stroma surrounding squamous cell carcinoma tumors was associated with reduced 5-year recurrence-free survival and overall survival rates. The study suggests that targeting the tumor microenvironment may be a meaningful approach for developing treatment strategies.
A new, cost-effective method for detecting ALK rearrangement in non-small cell lung cancer patients has been developed. This approach is comparable to the established gold standard, fluorescence in situ hybridization (FISH), and could enable more patients to access potentially life-saving crizotinib therapy.
A new study published in the Journal of Thoracic Oncology found that endosonography followed by surgical staging significantly improved the quality of life for lung cancer patients. The study, which compared two strategies for mediastinal staging, showed no significant difference in costs between the two approaches.
The TEMLA procedure demonstrated a higher diagnostic yield than EBUS and EUS in detecting cancer in primary staging, with a sensitivity of 98.6% compared to 88.9% for EBUS/EUS. Additionally, TEMLA showed superior performance in restaging procedures, with a sensitivity of 95.5% and specificity of 100%.
Research suggests that adding an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux does not improve treatment outcomes for cancer patients with blood clots. In fact, median survival was shorter and VTE resolution rates were lower in patients who received both treatments.
A Phase III trial found that amrubicin significantly improved tumor shrinkage, symptom control, and progression-free survival compared to topotecan in lung cancer patients. Patients treated with amrubicin also reported better quality of life and fewer adverse events.
New treatment options, including stereotactic ablative radiotherapy, have led to significant improvements in the survival of elderly Dutch lung cancer patients. Median survival for NSCLC patients increased by nearly 8 months between 2003 and 2009.
The Cancer Risk Management model uses dynamic simulations to project realistic Canadian populations, offering insights into screening, prevention, and treatment changes. By reducing smoking rates, the model predicts a decrease in lung cancer incidence and cumulative savings in direct treatment costs.
The study found that trusts with more pure thoracic surgeons saw a significant increase in lung cancer resection rates. In 2009, the overall resection rate rose by 46% due to increased investment in thoracic surgical expertise.
Research reveals disparities in trial populations reflecting U.S. demographics, with women and older patients under-enrolled. Minority groups also show significant underrepresentation, highlighting concerns about toxicity and treatment efficacy.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
Research reveals that lung adenocarcinomas in never-smokers exhibit greater genome instability and altered genetic patterns compared to those in smokers. The findings suggest distinct molecular mechanisms driving the development of lung cancer in never-smokers, potentially requiring unique treatments.
A new study reveals that ALK rearrangement affects nearly 10% of lung cancer patients, while MET amplification occurs in another 4.1%. This could lead to targeted therapy options like crizotinib for these patients.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
The International Association for the Study of Lung Cancer (IASLC) welcomed the publication of positive results from the National Lung Screening Trial, which showed a 20% reduction in lung cancer deaths and a 7% decrease in all-cause mortality among heavy smokers screened with low-dose spiral computed tomography. The trial followed ove...
Researchers found Asian non-small cell lung cancer patients survived longer than Caucasians regardless of the number of chemotherapy drugs given, with improved survival rates after targeted therapies were introduced in the early 2000s.
Five advocacy organizations from India, Australia and the US have been granted travel awards by IASLC to attend the 14th World Conference on Lung Cancer in Amsterdam. The winners will enjoy free registration, accommodation and travel expenses, as well as free IASLC affiliate membership.
Researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic effect on all mesothelioma cells. The study suggests using mTOR inhibitors as a novel anti-mesothelioma strategy, particularly in combination with chemotherapy.
A recent study published in the Journal of Thoracic Oncology found that soy isoflavones can sensitize cancer cells to radiation, increasing killing efficiency while protecting normal lung tissue from damage. Researchers used a soy mixture consisting of genistein, daidzein and glycitein to demonstrate this effect.
The new TNM 7 lung cancer staging system better predicts local or regional recurrence after surgery, according to a study published in the Journal of Thoracic Oncology. The updated system improved accuracy for predicting disease recurrence among patients with non-small cell lung cancer.
Small-screen detected lung cancers with maxSUV of 2.0 or smaller nodules than 10mm have low risk of nodal metastases, suggesting some patients can avoid invasive procedures. This reduces operating time and morbidity associated with lymph node dissection.
Researchers suggest that quitting smoking suddenly may be an early symptom of lung cancer. A study found that 48% of patients with lung cancer had quit before diagnosis, most without noticing any symptoms.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
A new international multidisciplinary classification of lung adenocarcinoma has been published by three top lung associations. The classification takes a comprehensive approach, incorporating advances in genetics, clinical information, and molecular studies to improve diagnosis and treatment.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
Researchers found lung adenocarcinomas in young patients with pediatric cancers, displaying similar gene mutations as adult cases. The tumors may occur prior to chemotherapy treatment and are not always secondary malignancies.
The TRUST study found that erlotinib significantly increased survival for patients with previously treated advanced NSCLC. Certain patient groups, such as adenocarcinoma, women, and Asian ethnicity, showed greater tumor responses to EGFR TK inhibitors.
A new study published in the Journal of Thoracic Oncology found that approximately half of advanced non-small cell lung cancer patients received chemotherapy treatment, exceeding previous estimates. The retrospective analysis showed age and insurance type were associated with chemotherapy administration.
A study found that tumor budding is a distinct morphologic feature with biologic and prognostic significance in lung adenocarcinoma, significantly linked to aggressive disease characteristics. The presence of tumor budding was also associated with lower five-year survival rates.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...
Research published in the Journal of Thoracic Oncology defines timeframes for declaring early stage lung cancer cured. Patients with stage IA NSCLC without vascular invasion can be considered cured after five years, while those with vascular invasion require longer follow-up until at least nine years.
A study of 342 early-stage lung cancer survivors found that nearly 60% experienced long-term dyspnea, with associated risk factors including reduced physical activity and depression. Targeting post-treatment rehabilitation strategies to improve breathlessness may be effective in improving outcomes.
A new method of tissue banking enables researchers to obtain high-quality RNA samples from lung tumor biopsies, increasing the number and type of tumors available for gene expression studies. This improves personalized medicine prospects for lung cancer patients.
Researchers found that administering nab-paclitaxel weekly resulted in a 48% response rate and less severe side effects compared to every-three-week dosing. The study showed improved anti-tumor activity and reduced nerve damage with the novel formulation.
Researchers analyzed surgical outcomes of non-small cell lung cancer patients over 30 years, finding improved survival rates with earlier stage diagnoses. The increase in patients diagnosed with early-stage adenocarcinoma is thought to contribute significantly to the favorable results.